MEF2D and breast cancer: Because knockdown of AKT expression by RNAi was incomplete, it was not possible to rule out that SIK2 inhibition of AKT signaling might contribute to the enhancement of PARP inhibitor sensitivity in ovarian and breast cancers through a class-IIa HDACs/MEF2D–independent pathway.